Amaros Closes Series A Financing and Forms Advisory Board to Advance Ophthalmic AI Platform

Amaros has announced the successful closure of its Series A financing round, supported by a group of new and existing investors. This funding milestone will enable the company to scale globally and accelerate the development and commercialization of its AI-powered platform, EvidenceEngine.

Fueling the Next Stage of Ophthalmic Innovation

While specific financial terms were not disclosed, the Series A funding will be used to:

       • Advance product development

       • Expand commercial partnerships

       • Grow Amaros’ engineering, clinical, and data science teams

“This funding confirms our core belief that ophthalmology’s most underutilized asset is its own data,” said Vartan Ghazarossian, PhD, co-founder and CEO of Amaros. “Too much critical information remains siloed—limiting how we study, diagnose and treat eye diseases. With our AI-powered EvidenceEngine, we’re building the industry’s first dynamic real-world intelligence platform, empowering physicians, researchers and companies to transform unstructured data into life-changing insights.”

Strategic Advisory Board to Guide Global Vision

Amaros has also formed an advisory board comprising distinguished experts in retinal and anterior segment care, artificial intelligence, and clinical trial design. The board will guide the strategic rollout of the EvidenceEngine and support its integration across ophthalmology’s evolving data ecosystem.

Advisory Board Members:

       • David S. Boyer, MD – Senior Partner at Retina-Vitreous Associates Medical Group (Los Angeles); lead investigator in AMD and diabetic retinopathy; adjunct clinical professor at USC/Keck School of Medicine.

       • David Eichenbaum, MD – Partner and Research Director at Retina Vitreous Associates of Florida; expert in retina-focused pharma development and trial execution.

       • Peter K. Kaiser, MD – Chaney Family Endowed Chair in Ophthalmology Research, Cole Eye Institute, Cleveland Clinic; professor at Case Western Reserve; global leader in retinal imaging and trial design.

       • T. Y. Alvin Liu, MD – Endowed professor in AI at Wilmer Eye Institute, Johns Hopkins University; inaugural director of JHU’s dedicated AI Innovation Center in Medicine.

       • Sumit P. Shah, MD – Partner at NJ Retina, Prism Vision Group; clinical associate professor at Rutgers; experienced investigator in retina clinical trials.

       • Michael A. Singer, MD – Clinical professor at UT Health Science Center; director of clinical research at Medical Center Ophthalmology Associates; authority on real-world data and imaging biomarkers.

       • Vance Thompson, MD – Founder of Vance Thompson Vision; pioneer in refractive and cataract surgery; expert in anterior segment innovation and clinical trial leadership.

“Our advisory board brings together visionary leaders with deep expertise in clinical excellence, real-world evidence and business innovation,” said Ben Toker, co-founder and president of Amaros. “Their insights will be pivotal as we transform fragmented and siloed data into precision intelligence—advancing clinical research, enhancing care delivery, and driving smarter commercialization. With their partnership, we are accelerating the adoption of ophthalmic AI and building the unified ecosystem that modern eye care demands.”